NEW YORK, NY--(Marketwire - Oct 2, 2012) - The anti-obesity drug market has garnered increased attention from investors this year as two weight loss drugs have gained approval from the U.S. Food and Drug Administration, the first approvals in over 13 years. The last weight loss drug to gain approval from the FDA was Roche Holdings Xenical in 1999. Five Star Equities examines the outlook for companies in the Biotechnology Industry and provides equity research on Arena Pharmaceuticals, Inc. (
Access to the full company reports can be found at:
The FDA has labeled obesity as a "major public health concern." According to data from the Centers for Disease Control and Prevention approximately 36 percent of all adults in the U.S. are "obese." A study in the American Journal of Preventive Medicine forecasted that from now to 2030 a total of $550 billion will be spent on health care as a result of rapidly rising obesity rates.
"By the year 2030, at least 44 percent of adults in every state of the country could be obese," said Jeffrey Levi, the executive director of Trust for America's Health. "The potential rise in health-related problems associated with obesity and the rise in health care costs could be staggering."
Five Star Equities releases regular market updates on the Biotechnology Industry so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at www.FiveStarEquities.com and get exclusive access to our numerous stock reports and industry newsletters.
Arena Pharmaceuticals is a biopharmaceutical company focused on discovering, developing and commercializing novel drugs for weight management, cardiovascular disease, inflammation and other disorders. The company's weight loss drug, Belviq, was approved by the FDA in June.
VIVUS is a biopharmaceutical company commercializing and developing innovative, next-generation therapies to address unmet needs in obesity, sleep apnea, diabetes and sexual health for U.S., Europe and other world markets. The company's weight loss drug, Qsymia was approved by the FDA in July. Bloomberg recently reported that Qsymia was covered by insurers approximately 30 percent of the time during its first week on the market.
Five Star Equities provides Market Research focused on equities that offer growth opportunities, value, and strong potential return. We strive to provide the most up-to-date market activities. We constantly create research reports and newsletters for our members. Five Star Equities has not been compensated by any of the above-mentioned companies. We act as an independent research portal and are aware that all investment entails inherent risks. Please view the full disclaimer at: